Rapid Genome Sequencing Diagnostic Study Implemented for Cancer Patients
Rapid whole-genome sequencing (rWGS) identifies actionable cancer variants and mutational signatures directly from patient samples, according to a clinical study registered at ClinicalTrials.gov under NCT07201038 and approved by the Health Research Authority and Health and Care Research Wales, evaluates sequencing workflows to accelerate clinical reporting for individuals with cancer or suspected cancer.
Illumina TruPath Genome technology generates rWGS data
Patient recruitment ran between April 2023 and March 2025 following written informed consent from participants or their parents and legal guardians. Sample handling and DNA extraction for solid tumors and archival specimens took place adhering to Human Tissue Act guidance. Illumina TruPath Genome technology generated the rWGS data, facilitating rapid variant calling for structural variants, gene fusions, single nucleotide variants, insertions, deletions, and copy number alterations.
In parallel, the clinical samples underwent routine NHS GMS whole-genome sequencing alongside conventional molecular diagnostics. These standard methods included fluorescent in situ hybridization, single nucleotide polymorphism analysis, RNA-sequencing, targeted next-generation panels, real-time polymerase chain reaction, and immunohistochemistry. Clinically actionable variants detected via rWGS required orthogonal confirmation through standard-of-care molecular testing before guiding patient management decisions.
Clinicians review reports during weekly advisory board meetings
Turnaround time measured the interval between the availability of all required tumor and germline samples and the issuance of a clinically interpretable report. This metric incorporated DNA extraction, transfer, sequencing, and analysis steps. Data integration relied on a centralized data extraction protocol validated by multiple team members. Clinicians reviewed completed analyses during weekly pediatric genomic tumor advisory board meetings prior to official report generation.
In a related context regarding rapid sequencing applications, genetic conditions frequently appear in intensively ill children, showing that fast genomic diagnostics are useful in acute pediatric settings. However, the primary findings detailed in the study center specifically on oncology workflows, tumor mutational burden calculations, and mutational signature decompositions derived from whole-genome data.
What sequencing platform and analysis methods were used?
What sequencing platform was used in the clinical study?
The study utilized Illumina TruPath Genome technology, which uses on-flow cell library preparation and proximity information from neighboring nanowells to generate long-range genomic data.
How were hematological cancer samples analyzed?
Hematological cancer samples were analyzed in tumor-only mode using fresh peripheral blood, bone marrow, or crude lysates, as paired germline material was absent for those cases.
What validation steps were required for actionable variants?
Clinically actionable variants identified through rapid whole-genome sequencing required orthogonal confirmation using NHS standard-of-care molecular testing before informing clinical management.
Worth a look